MPMahsa Panahishokouh

Mahsa Panahishokouh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahsa Panahishokouh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medication discrepancies and medication-related problems in psychiatric patients: A medication reconciliation study

    by Mozhdeh Shahabi, Mahsa Panahishokouh, Niayesh Mohebbi

    Medication discrepancies (MDs) are common medication errors that can lead to adverse drug events (ADEs) and suboptimal treatment. Medication reconciliation (MR) programs are implemented in many countries, including Iran, to identify, resolve, and prevent MDs and other medication-related problems (MRPs). In the psychiatric setting, the importance of identifying and addressing MRPs is even greater due to the high prevalence of polypharmacy, limited patient cooperation, and other factors. This study aimed to comprehensively investigate the prevalence of MDs and MRPs in psychiatric patients. This study included 302 psychiatric patients receiving at least two systemic medications daily. Their medications were reviewed at discharge using the Pharmaceutical Society of Australia (PSA) guidelines to identify MRPs. The collected data were analyzed statistically. In this study, patients were taking a total of 1421 medications (4.71 medications per patient). A total of 493 MDs and 392 MRPs were identified. The most common MRPs were, in decreasing order, medication underuse or non-adherence by the patient (175 cases, 44.64% of all MRPs) and drug interactions (168 cases, 42.85%). The number of drug interactions significantly increased with the increasing number of underlying diseases and the number of medications used (P < 0.001 in both cases). The findings of this study indicate a high prevalence of medication-related problems (MRPs) in psychiatric settings, highlighting the critical role of MR programs in mitigating such risks. Among the challenges identified, non-adherence to treatment and potential drug interactions emerged as the most significant issues affecting psychiatric patients.

  • Open Access

    Antipsychotics-Associated Allergic Reaction: A Case Report and Review of Literature

    by Fatemeh Sadeghi, Mahnaz Momenzadeh, Mahsa Panahishokouh

    Hypersensitivity reactions to second-generation antipsychotics and mood stabilizers are uncommon and can lead to serious complications. These medicines are generally well tolerated, but there have been reports of unusual allergic reactions, such as hives or itching, associated with these drugs. The patient is a 45-year-old woman who presented with a recurrence of a manic episode of bipolar I disorder and developed skin complications and itching after receiving valproate and levetiracetam. She subsequently experienced severe skin allergic reactions, including hives and itching, after taking various second-generation antipsychotics, including risperidone, aripiprazole, and quetiapine. These allergic reactions occurred shortly after starting the medication and resolved after discontinuing the drug. The purpose of this case report is to highlight the importance of being aware of the possibility of concomitant hypersensitivity with various antipsychotic and anticonvulsant medications, which can affect the diagnosis and treatment of the disease.


  • Open Access

    Visual Disturbances Associated With Statins: A Case Report and Literature Review

    by Abdolamir Atapour, Mahsa Panahishokouh, Mahnaz Momenzadeh

    Statins are a class of drugs that are vital for lowering blood lipid levels and reducing the risk of both primary and secondary cardiovascular diseases. These drugs are generally considered safe; however, some individuals may experience side effects, such as muscle pain, headache, fatigue, myopathy, and gastrointestinal disorders. One of the less frequently reported side effects of statins is visual disturbances. We report the case of a 51-year-old woman who developed persistent headache, blurred vision, and diplopia shortly after initiating Atorvastatin. These visual disturbances recurred when treatment was switched to Rosuvastatin and Lovastatin. Comprehensive neurological evaluation, including brain MRI, was unremarkable. All symptoms resolved completely after permanent discontinuation of statin therapy, indicating a rare but significant statin-associated visual adverse event. Due to the significance of reporting this complication, this study aims to present a case of a patient who experienced visual impairment associated with the use of atorvastatin, rosuvastatin, and, to a lesser extent, lovastatin.


  • Open Access

    Assessment of Medication Adherence and Related Factors in Children and Adolescents with Cystic Fibrosis: A Pharmacist-Led Study

    by Mahsa Panahishokouh, Amir Kasaeian, Saedeh Sadat Jafarrangraz, Shahideh Amini

    Background: Medication non-adherence in cystic fibrosis (CF) can lead to reduced drug efficacy and suboptimal care. Objectives: This study aimed to evaluate adherence to commonly used medications and related factors among children and adolescents with CF. Methods: A research pharmacist assessed drug adherence using the 5-item Medication Adherence Rating Scale (MARS-5) through face-to-face interviews with patients and their parents. Based on the MARS-5 score, patients were categorized as having perfect (≥ 25) or lower (< 25) treatment adherence. Results: A total of 300 patients were included in the study. Between 42.0% and 87.9% of patients were lower-adherent in at least one aspect of their treatment. Among those who received all medications, 86.9% were lower-adherent. Specifically, 42.0% of patients had lower adherence to inhalants, 67.6% to systemic antibiotics, 81.4% to gastrointestinal agents, and 87.9% to nutritional supplements. Factors significantly associated with adherence included the number of drugs for inhalants and systemic antibiotics; the mother’s education level for inhalants, systemic antibiotics, and gastrointestinal agents; and distance from the medical center for inhalants and nutritional supplements (all P < 0.05). Conclusions: Non-adherence to inhalants, systemic antibiotics, gastrointestinal agents, and nutritional supplements is common among children and adolescents with CF. Adherence to one class of medication does not predict adherence to others. A high number of drugs, a low mother’s education level, and a long distance from the medical center decrease the likelihood of perfect adherence to CF medications.

  • Open Access

    The Efficacy and Safety of Fluoxetine Delayed-Release 90 mg/Weekly in Psychiatry: An Evidence-Based Mini-Review

    by Niayesh Mohebbi, Mahtab Motamed, Mahsa Panahishokouh

    Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.

  • Open Access

    Metronidazole induced anaphylactic shock: a case report

    by Mahsa Panahishokouh, Nafiseh Sadat Alizadeh, Mehrnoush Dianatkhah, Mina Borran, Behnam Behnoush

    Metronidazole induced anaphylactic shock is an extremely rare drug reaction. We reported a 39-year-old man with severe anaphylactic shock caused by Metronidazole. He denied history of food or drugs allergy. Severe cardiovascular collapse suddenly occurred after receiving intravenous Metronidazole. The patient was successfully managed as a case of anaphylactic shock and finally discharge.